PEC vs BioGend Therapeutics: monthly revenue

Monthly revenue and year-on-year change for PEC (6446) and BioGend Therapeutics (6733) over the past 13 months. The chart compares year-on-year growth rather than amounts, since the companies differ in size.

Year-on-year change

━ PEC ━ BioGend Therapeutics

0%+108%-20%25/1026/0126/0426/0726/10

Monthly revenue history

MonthPECYoYBioGend TherapeuticsYoY
Oct 2026NT$2.84 billion+102.0%NT$21.4 million+24.8%
Sep 2026NT$2.64 billion+100.0%NT$21.4 million+9.5%
Aug 2026NT$2.62 billion+105.4%NT$19.3 million+9.3%
Jul 2026NT$2.51 billion+92.6%NT$19.7 million-19.5%
Jun 2026NT$2.33 billion+94.9%NT$23.8 million+63.6%
May 2026NT$2.46 billion+108.5%NT$16 million-14.5%
Apr 2026NT$2.06 billion+68.3%NT$19.6 million+0.9%
Mar 2026NT$1.94 billion+64.4%NT$16.6 million+10.4%
Feb 2026NT$1.6 billion+56.7%NT$15.3 million+1.4%
Jan 2026NT$1.58 billion+49.8%NT$23 million+32.9%
Dec 2025NT$1.92 billion+69.9%NT$23.2 million+15.5%
Nov 2025NT$1.55 billion+53.0%NT$20.1 million+43.8%
Oct 2025NT$1.4 billion+53.6%NT$17.1 million-0.8%

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16